APA (7th ed.) Citation

Martinez-Lago, N. P., Alonso de Castro, B., Reboredo Rendo, C., Calleja, T., Gómez-Randulfe Rodríguez, M. I., Silva Diaz, S., . . . Reboredo Lopez, M. (2023). Effect of Tabernero's prognostic subgroups or development of neutropenia on survival outcomes of patients with refractory metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil plus bevacizumab (TASBEV) in real-world practice. Journal of clinical oncology, 41(4_suppl), 99. https://doi.org/10.1200/JCO.2023.41.4_suppl.99

Chicago Style (17th ed.) Citation

Martinez-Lago, Nieves P., et al. "Effect of Tabernero's Prognostic Subgroups or Development of Neutropenia on Survival Outcomes of Patients with Refractory Metastatic Colorectal Cancer (mCRC) Treated with Trifluridine/tipiracil Plus Bevacizumab (TASBEV) in Real-world Practice." Journal of Clinical Oncology 41, no. 4_suppl (2023): 99. https://doi.org/10.1200/JCO.2023.41.4_suppl.99.

MLA (9th ed.) Citation

Martinez-Lago, Nieves P., et al. "Effect of Tabernero's Prognostic Subgroups or Development of Neutropenia on Survival Outcomes of Patients with Refractory Metastatic Colorectal Cancer (mCRC) Treated with Trifluridine/tipiracil Plus Bevacizumab (TASBEV) in Real-world Practice." Journal of Clinical Oncology, vol. 41, no. 4_suppl, 2023, p. 99, https://doi.org/10.1200/JCO.2023.41.4_suppl.99.